Breaking News

SK pharmteco Acquires Controlling Interest in CBM

Expands technical expertise, production capacity, and geographic reach.

SK pharmteco is acquiring a controlling interest in Philadelphia-based cell and gene therapy CDMO Center for Breakthrough Medicines (CBM), expanding SK pharmteco’s technical expertise, production capacity, and geographic reach. The announcement follows an initial $350 million capital investment in 2022 and SK pharmteco’s acquisition of Yposkesi, a French viral vector CDMO, in March 2021. Once the new deal is finalized, SK pharmteco will have a controlling stake in CBM, and the operations of C...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters